Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 02:07 pm IST
Share
Heilongjiang ZBD Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 2,703.01 million compared to CNY 1,775.13 million a year ago. Revenue was CNY 2,704.74 million compared to CNY 1,780.78 million a year ago. Net income was CNY 242.42 million compared to CNY 240.82 million a year ago. Basic earnings per share from continuing operations was CNY 0.2855 compared to CNY 0.2836 a year ago. Diluted earnings per share from continuing operations was CNY 0.2855 compared to CNY 0.2836 a year ago.
HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.